Sonora Investment Management Group LLC Sells 1,140 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sonora Investment Management Group LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 4.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,161 shares of the biotechnology company’s stock after selling 1,140 shares during the period. Sonora Investment Management Group LLC’s holdings in Exelixis were worth $738,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. FMR LLC grew its position in shares of Exelixis by 6.1% during the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after purchasing an additional 140,568 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. Two Sigma Advisers LP increased its stake in Exelixis by 6.1% in the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock worth $44,182,000 after acquiring an additional 98,000 shares during the last quarter. Systematic Financial Management LP raised its holdings in shares of Exelixis by 7.1% in the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock valued at $30,320,000 after acquiring an additional 77,599 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its position in shares of Exelixis by 24.6% during the 3rd quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock valued at $23,653,000 after acquiring an additional 180,021 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Exelixis

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 96,986 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $35.00, for a total transaction of $3,394,510.00. Following the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. The trade was a 16.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 208,574 shares of company stock worth $7,376,374 over the last three months. 2.85% of the stock is currently owned by company insiders.

Exelixis Trading Down 0.1 %

EXEL opened at $32.93 on Friday. Exelixis, Inc. has a 12-month low of $20.01 and a 12-month high of $37.59. The company has a market cap of $9.40 billion, a price-to-earnings ratio of 21.11, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. The stock has a fifty day simple moving average of $34.73 and a two-hundred day simple moving average of $30.01.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. Exelixis’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. On average, analysts predict that Exelixis, Inc. will post 1.74 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on EXEL shares. Brookline Capital Management began coverage on shares of Exelixis in a research report on Monday, December 23rd. They issued a “buy” rating for the company. The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Truist Financial upped their target price on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday. Piper Sandler lifted their price target on shares of Exelixis from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. Finally, Stephens reaffirmed an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a report on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.